Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
Lin
Kai
K
Novartis Institutes for Biomedical Research, Inc., Cambridge, MA 02139, USA. kai.lin@novartis.com
Karwowska
Sylwia
S
Lam
Eric
E
Limoli
Kay
K
Evans
Thomas G
TG
Avila
Claudio
C
D019380:Anti-HIV Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000821:virology; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D009705:Nucleosides / Q000008:administration & dosage / Q000494:pharmacology*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000494:pharmacology*; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D009705:Nucleosides; D011744:Pyrimidinones; D000077712:Telbivudine; C413685:entecavir; D006147:Guanine; D013936:Thymidine